https://en.bioecon.ru/companies/eligo-bioscience/Recent content in Eligo-Bioscience on BioeconHugoen-USWed, 29 Jul 2026 13:42:49 +0700https://en.bioecon.ru/technology/genome-editing/Wed, 24 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/genome-editing/Programmable genome editors — CRISPR-Cas9, base editors and prime editors — delivered ex vivo or in vivo via lipid nanoparticles to treat genetic disease, from the first approved CRISPR therapy Casgevy to in-vivo redosable CRISPR and single-dose cardiovascular base editing.https://en.bioecon.ru/technology/bacteriophage-therapy/Mon, 01 Jan 0001 00:00:00 +0000https://en.bioecon.ru/technology/bacteriophage-therapy/Utilizing naturally occurring or precision-engineered bacterial viruses to selectively target and eradicate specific pathogenic bacterial strains without harming the microbiome.